Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Opening Achievement: 8 Methodologies for Compelling Using time productively- In a scientific first, biologists recorded a wild wolf potentially using tools
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- This Week In Space podcast: Episode 187 — An Inspired Enterprise
- Vote In favor of Your Favored Web-based Book Retailor
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
